Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atomoxetine + coenzyme Q10
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of atomoxetine, a selective norepinephrine reuptake inhibitor (NRI), and coenzyme Q10, an antioxidant supplement. This combination has been studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), particularly in patients who have not fully responded to atomoxetine alone. The addition of coenzyme Q10 to atomoxetine has shown improved ADHD symptoms, especially hyperactivity, impulsivity, and learning problems, with minimal additional adverse effects.
- Other names
- atomoxetine + ubiquinoneatomoxetine + CoQ10
02
Targets
ND1 (Mitochondrial electron transport chain complex I)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on atomoxetine + coenzyme Q10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atomoxetine + coenzyme Q10.